Carol Swetlik
Neurology · Cleveland, OHNPI 1245791573
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,365 of the $7,352 with a category attached, or 73.0%. 9 manufacturers reported payments, led by Amgen at 45.4% of the total. Reporting peaked in 2024 at $7,041 and has fallen 98.1% since, to $136 in 2025.
Across 22 payments — averaging $334.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Genentech USA, Inc.$3K
- Bristol Myers Squibb$281
- AstraZeneca$141
- Genentech, Inc.$134
- Biogen$96
- plus $107 from 3 others
What the payments were for
- Consulting fees$5,36573%
- Travel & lodging$3004%
- Food & beverage$1,68723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $3,341 |
| Genentech USA, Inc. | 5 | $3,251 |
| Bristol Myers Squibb | 3 | $281 |
| AstraZeneca | 2 | $141 |
| Genentech, Inc. | 1 | $134 |
| Biogen | 1 | $96 |
| Jazz Pharmaceuticals Inc. | 1 | $48 |
| Novartis | 1 | $40 |
| TG Therapeutics, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,352 in reported general payments places this provider in the 70th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 15 | $183,793 |
| Gabapentin | 12 | $110 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cleveland
- Imad NajmCleveland$373K
- Hesham AbboudCleveland$363K
- Robert BermelCleveland$302K
- Eric BaronCleveland$297K
- Robert FoxCleveland$296K
- Aarushi SunejaCleveland$269K
- Mary WillisCleveland$254K
- Benjamin WalterCleveland$210K
- Aasef ShaikhCleveland$186K
- Maryann MaysCleveland$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.